- Home
- DMF vs TIL Comparison
DMF vs TIL Comparison
Compare DMF & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMF
- TIL
- Stock Information
- Founded
- DMF 1988
- TIL 2018
- Country
- DMF United States
- TIL United States
- Employees
- DMF N/A
- TIL N/A
- Industry
- DMF Finance/Investors Services
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DMF Finance
- TIL Health Care
- Exchange
- DMF Nasdaq
- TIL Nasdaq
- Market Cap
- DMF 152.2M
- TIL 171.7M
- IPO Year
- DMF N/A
- TIL 2021
- Fundamental
- Price
- DMF $7.01
- TIL $13.03
- Analyst Decision
- DMF
- TIL Buy
- Analyst Count
- DMF 0
- TIL 5
- Target Price
- DMF N/A
- TIL $114.00
- AVG Volume (30 Days)
- DMF 60.7K
- TIL 170.9K
- Earning Date
- DMF 01-01-0001
- TIL 05-20-2025
- Dividend Yield
- DMF 2.66%
- TIL N/A
- EPS Growth
- DMF N/A
- TIL N/A
- EPS
- DMF 0.15
- TIL N/A
- Revenue
- DMF N/A
- TIL N/A
- Revenue This Year
- DMF N/A
- TIL N/A
- Revenue Next Year
- DMF N/A
- TIL N/A
- P/E Ratio
- DMF $45.13
- TIL N/A
- Revenue Growth
- DMF N/A
- TIL N/A
- 52 Week Low
- DMF $5.37
- TIL $9.62
- 52 Week High
- DMF $6.79
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DMF 49.51
- TIL 43.50
- Support Level
- DMF $6.93
- TIL $11.97
- Resistance Level
- DMF $7.04
- TIL $14.67
- Average True Range (ATR)
- DMF 0.08
- TIL 2.04
- MACD
- DMF 0.02
- TIL -0.10
- Stochastic Oscillator
- DMF 66.67
- TIL 16.40
About DMF BNY Mellon Municipal Income Inc.
BNY Mellon Municipal Income, Inc. is a non-diversified closed-end management investment company. Its investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. The fund invests in municipal obligations that are rated investment grade and have maturities of less than one year. The company targets to invest in the sector such as education, pre-refunded muni, utility, transportation, healthcare, special tax, state/territory general obligations, industry revenue, and pollution control.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.